CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

OnabotulinumtoxinA

Last Updated: August 15, 2013
Result type: Reports
Project Number: SR0345
Product Line: Reimbursement Review

Generic Name: OnabotulinumtoxinA

Brand Name: Botox

Manufacturer: Allergan Inc.

Indications: Migraine, chronic

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: May 28, 2014

Recommendation Type: Do not list

Request for Resubmission: Eligible (June 5, 2018)